We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Immunoaffinity Technology Distinguishes Between Lyme Disease Infection States and Tracks Treatment Response

By LabMedica International staff writers
Posted on 25 Oct 2022

Lyme disease is the most prevalent vector-borne disease in the U. More...

S., with an estimated 476,000 annual cases. Current diagnostics for this disease and complicated and rely on indirect methods that suffer from low sensitivity and high false-positive rates. Furthermore, they are unable to distinguish between newly infected patients and patients that have received prior treatment. This makes it impossible to determine treatment efficacy, track disease resolution or diagnose subsequent infections. Now, researchers have demonstrated that it is possible to distinguish between Lyme disease infection states and track treatment response using a proprietary immunoaffinity technology.

Using GlycoPath Inc.’s (Charleston, SC, USA) proprietary GlycoTyper immunoaffinity technology, researchers identified glycosylation changes that differentiate acute Lyme disease and track with treatment. By utilizing the GlycoTyper methodology on a small cohort of patients, researchers were able to distinguish between control, acute and treated patients with a specificity of 94.7-100%. The study has revealed a new research avenue of immune dysregulation associated with the disease that is expected to contribute to the accurate and prompt treatment of Lyme disease patients.

Prior to this study, the proprietary GlycoTyper methodology had only been applied to liver diseases. Earlier this year, results from the first GlycoFibroTyper study had shown that the GlycoFibroTyper assay was able to detect liver fibrosis and cirrhosis, the pre-malignant pre-cursor to hepatocellular carcinoma (HCC), with a higher sensitivity and specificity and overall accuracy than current standard of care. Furthermore, this assay is significantly less invasive, suitable for continuous monitoring, and provides a measurement of the overall health status of the liver.

Related Links:
GlycoPath Inc. 


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
HbA1c Test
HbA1c Rapid Test
New
Malondialdehyde HPLC Test
Malondialdehyde in Serum/Plasma – HPLC
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Pathology

view channel
Image: AI-analyzed images from the FDM microscope show platelet clumps in motion (Photo courtesy of Hirose et al CC-BY-ND)

AI Microscope Spots Deadly Blood Clots Before They Strike

Platelets are small blood cells that act as emergency responders in the body, rushing to areas of injury to help stop bleeding by forming clots. However, sometimes platelets can overreact, leading to complications.... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.